Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459573 | 1.00 | EPHX1 (0.47) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL459574 | 1.00 | EPHX1 (0.47) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| Hydrochloric Acid SCHEMBL10476064 | 0.98 | EPHX1 (0.46) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL2494230 | 0.95 | EPHX1 (0.55) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL2494231 | 0.95 | EPHX1 (0.55) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL7616231 | 0.93 | MME (0.42) | EPHX1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL16124605 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL7770681 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL16124602 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE | |
| SCHEMBL7770680 | 0.93 | EPHX1 (0.58) | EPHX1SMN1; SMN2NPC1RAB9AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| EP-3265448-A1 | RILUZOLE PRODRUGS AND THEIR USE | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2018-01-10 | — | — | EP | disclosed |
| WO-2016185423-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016140879-A9 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016140878-A9 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2016-10-20 | — | — | WO | disclosed |
| EP-2410857-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111058-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-1727526-A2 | PIPERAZINE UREA DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | Schering Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| EP-1664001-A2 | BIARYL HETEROCYCLIC AMINES, AMIDES, AND SULFUR-CONTAINING COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005079769-A2 | PIPERAZINE DERIVATIVES FOR THE TREATMENT OF ENDOMETRIOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-09-01 | — | — | WO | disclosed |
| EP-1204654-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001070708-A1 | SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1087935-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 2001-04-04 | — | — | EP | disclosed |
| WO-2001009111-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| EP-0942906-A2 | COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1999-09-22 | — | — | EP | disclosed |
| EP-0934291-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934291-A4 | — | SMITHKLINE BEECHAM CORP (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998030558-A2 | TRICYCLIC COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1997016433-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | EPHX1 148/4885SMN1; SMN2 96/4885NPC1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.